WaferGen Announces Delay in Reporting of Second Quarter 2011 Results
FREMONT, Calif. — WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, announced today that it intends to file its Quarterly Report on Form 10-Q for the period ended June 30, 2011 within two weeks. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission relating to its Form 10-Q filing.
In order to complete its financial statements and other information contained in the Quarterly Report on Form 10-Q, the company needs additional time to finalize the valuation amounts and related accounting treatment of convertible preferred stock, convertible notes and warrants issued on May 27, 2011 in the company’s $30.6 million private placement financing.
About WaferGen Biosystems, Inc.
WaferGen Biosystems, Inc. develops, manufactures and sells state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries to advance next generation sequencing and ultimately personalized medicine. WaferGen offers the breakthrough SmartChip Real-Time PCR System, a next-generation Real-Time PCR system for discovery and validation of gene expression patterns (biomarkers) on a single platform. For additional information, please see https://www.wafergen.com.

